FutureGen

Showing 1 posts of 1 posts found.

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024
Research and Development FutureGen, Gastrointestinal tract, ibd, inflammatory bowel disease

AbbVie and FutureGen Biopharmaceutical have announced a license agreement for the development of FG-M701, a next-generation TL1A antibody for the …

Latest content